Identification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosa

Infection and Immunity

Volumn 83, Issue 8, 2015, Pages 3006-3014

  Mishra, Meenu ^a   Ressler, Adam ^b   Schlesinger, Larry S ^a,b   Wozniak, Daniel J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; MONOCLONAL ANTIBODY; OUTER MEMBRANE PROTEIN; POLYCLONAL ANTIBODY; PROTEIN OPRF; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; OPRF PROTEIN, PSEUDOMONAS AERUGINOSA; PROTEIN BINDING;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; ESCHERICHIA COLI; FAR WESTERN BLOTTING; GRAM NEGATIVE BACTERIUM; HETEROLOGOUS EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTERNALIZATION; MASS SPECTROMETRY; NEUTROPHIL; NONHUMAN; OPRF GENE; OPSONIZATION; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PSEUDOMONADACEAE; PSEUDOMONAS AERUGINOSA; GENETICS; METABOLISM; MICROBIOLOGY; PSEUDOMONAS INFECTION;

BACTERIAL PROTEINS; COMPLEMENT C3B; HUMANS; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84937153792     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00081-15     Document Type: Article

References (51)

1. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. 2012. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 186:857-865. http://dx.doi.org/10.1164/rccm.201203-0507OC.
2. Garner HP, Phillips JR, Herron JG, Severson SJ, Milla CE, Regelmann WE. 2004. Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis. J Lab Clin Med 144:127-133. http://dx.doi.org/10.1016/j.lab.2004.04.010.
3. Benge GR. 1988. Bactericidal activity of human serum against strains of Klebsiella from different sources. J Med Microbiol 27:11-15. http://dx.doi .org/10.1099/00222615-27-1-11.
4. Mishra M, Byrd MS, Sergeant S, Azad AK, Parsek MR, McPhail L, Schlesinger LS, Wozniak DJ. 2012. Pseudomonas aeruginosa Psl polysac-charide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell Microbiol 14:95-106. http://dx.doi.org/10.1111/j.1462-5822.2011.01704.x.
5. Hostetter MK, Gordon DL. 1987. Biochemistry of C3 and related thiolester proteins in infection and inflammation. Rev Infect Dis 9:97-109. http://dx.doi.org/10.1093/clinids/9.1.97.
6. Joiner KA, Goldman RC, Hammer CH, Leive L, Frank MM. 1983. Studies onthemechanismof bacterial resistance to complement-mediated killin. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. J Immunol 131:2570-2575.
7. Gross GN, Rehm SR, Pierce AK. 1978. The effect of complement depletion on lung clearance of bacteria. J Clin Invest 62:373-378. http://dx.doi .org/10.1172/JCI109138.
8. Younger JG, Shankar-Sinha S, Mickiewicz M, Brinkman AS, Valencia GA, Sarma JV, Younkin EM, Standiford TJ, Zetoune FS, Ward PA. 2003. Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. AmJ Respir Cell Mol Biol 29:432-438. http://dx.doi.org/10.1165/rcmb.2002-0145OC.
9. Mueller-Ortiz SL, Drouin SM, Wetsel RA. 2004. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun 72:2899-2906. http://dx.doi.org/10.1128/IAI .72.5.2899-2906.2004.
10. Woods DE, Lam JS, Paranchych W, Speert DP, Campbell M, Godfrey AJ. 1997. Correlation of Pseudomonas aeruginosa virulence factors from clinical and environmental isolates with pathogenicity in the neutropenic mouse. Can J Microbiol 43:541-551. http://dx.doi.org/10.1139/m97-077.
11. Vogels MT, Cantoni L, Carelli M, Sironi M, Ghezzi P, van der Meer JW. 1993. Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice. Antimicrob Agents Chemother 37:2527-2533. http://dx.doi.org/10.1128/AAC.37.12.2527.
12. Sugawara E, Nestorovich EM, Bezrukov SM, Nikaido H. 2006. Pseudomonas aeruginosa porin OprF exists in two different conformations. J Biol Chem 281:16220-16229. http://dx.doi.org/10.1074/jbc.M600680200.
13. Azghani AO, Idell S, Bains M, Hancock RE. 2002. Pseudomonas aeruginosa outer membrane protein F is an adhesin in bacterial binding to lung epithelial cells in culture. Microb Pathog 33:109-114. http://dx.doi.org/10.1006/mpat.2002.0514.
14. Wu L, Estrada O, Zaborina O, Bains M, Shen L, Kohler JE, Patel N, Musch MW, Chang EB, Fu YX, Jacobs MA, Nishimura MI, Hancock RE, Turner JR, Alverdy JC. 2005. Recognition of host immune activation by Pseudomonas aeruginosa. Science 309:774-777. http://dx.doi.org/10.1126/science.1112422.
15. Martin NL, Rawling EG, Wong RS, Rosok M, Hancock RE. 1993. Conservation of surface epitopes in Pseudomonas aeruginosa outer membrane porin protein OprF. FEMS Microbiol Lett 113:261-266. http://dx .doi.org/10.1111/j.1574-6968.1993.tb06524.x.
16. Mansouri E, Gabelsberger J, Knapp B, Hundt E, Lenz U, Hungerer KD, Gilleland HE, Jr, Staczek J, Domdey H, von Specht BU. 1999. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 67:1461-1470.
17. Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB. 2009. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 77:2356-2366. http://dx.doi.org/10.1128/IAI.00054-09.
18. Edwards RA, Keller LH, Schifferli DM. 1998. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 207:149-157. http://dx.doi.org/10.1016/S0378-1119(97)00619-7.
19. Ma L, Jackson KD, Landry RM, Parsek MR, Wozniak DJ. 2006. Analysis of Pseudomonas aeruginosa conditional psl variants reveals roles for the psl polysaccharide in adhesion and maintaining biofilm structure postattachment. J Bacteriol 188:8213-8221. http://dx.doi.org/10.1128/JB.01202-06.
20. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chun-Rong L, Guenthner D, Bovee D, Olson MV, Manoil C. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 100:14339-14344. http://dx.doi.org/10.1073/pnas.2036282100.
21. Takeshita S, Sato M, Toba M, Masahashi W, Hashimoto-Gotoh T. 1987. High-copy-number and low-copy-number plasmid vectors for lacZ alphacomplementation and chloramphenicol-or kanamycin-resistance selection. Gene 61:63-74. http://dx.doi.org/10.1016/0378-1119(87)90365-9.
22. Byrd MS, Sadovskaya I, Vinogradov E, Lu H, Sprinkle AB, Richardson SH, Ma L, Ralston B, Parsek MR, Anderson EM, Lam JS, Wozniak DJ. 2009. Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. Mol Microbiol 73:622-638. http://dx .doi.org/10.1111/j.1365-2958.2009.06795.x.
23. Mizuno T, Kageyama M. 1978. Separation and characterization of the outer membrane of Pseudomonas aeruginosa. J Biochem 84:179-191.
24. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176:7566-7575. http://dx.doi.org/10.4049/jimmunol .176.12.7566.
25. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685. http://dx.doi.org/10.1038/227680a0.
26. Balagopal A, MacFarlane AS, Mohapatra N, Soni S, Gunn JS, Schlesinger LS. 2006. Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages. Infect Immun 74:5114-5125. http://dx.doi.org/10.1128/IAI .00795-06.
27. Rawling EG, Martin NL, Hancock RE. 1995. Epitope mapping of the Pseudomonas aeruginosa major outer membrane porin protein OprF. Infect Immun 63:38-42.
28. Galdiero F, Tufano MA, Sommese L, Folgore A, Tedesco F. 1984. Activation of complement system by porins extracted from Salmonella typhimurium. Infect Immun 46:559-563.
29. Toews GB, Vial WC, Hansen EJ. 1985. Role of C5 and recruited neutrophils in early clearance of nontypable Haemophilus influenzae from murine lungs. Infect Immun 50:207-212.
30. Larsen GL, Mitchell BC, Harper TB, Henson PM. 1982. The pulmonary response of C5 sufficient and deficient mice to Pseudomonas aeruginosa. Am Rev Respir Dis 126:306-311.
31. Leuzzi R, Nesta B, Monaci E, Cartocci E, Serino L, Soriani M, Rappuoli R, Pizza M. 2013. Neisseria gonorrhoeae PIII has a role on NG1873 outer membrane localization and is involved in bacterial adhesion to human cervical and urethral epithelial cells. BMC Microbiol 13:251. http://dx.doi .org/10.1186/1471-2180-13-251.
32. Barcena-Uribarri I, Thein M, Barbot M, Sans-Serramitjana E, Bonde M, Mentele R, Lottspeich F, Bergstrom S, Benz R. 2014. Study of the protein complex, pore diameter, and pore-forming activity of the Borrelia burgdorferi P13 porin. J Biol Chem 289:18614-18624. http://dx.doi.org/10.1074/jbc.M113.539528.
33. Reference deleted.
34. Reference deleted.
35. Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. 2014. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother 10:170-183. http://dx.doi.org/10.4161/hv.26565.
36. Ding B, von Specht BU, Li Y. 2010. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa. Vaccine 28:4119-4122. http://dx.doi.org/10.1016/j.vaccine.2010.04.028.
37. Alberti S, Alvarez D, Merino S, Casado MT, Vivanco F, Tomas JM, Benedi VJ. 1996. Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae. Infect Immun 64:4726-4732.
38. Bellinger-Kawahara C, Horwitz MA. 1990. Complement component C3 fixes selectively to the major outer membrane protein (MOMP) of Legionella pneumophila and mediates phagocytosis of liposome-MOMP complexes by human monocytes. J Exp Med 172:1201-1210. http://dx.doi.org /10.1084/jem.172.4.1201.
39. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 4:e00339-00313.
40. Mueller-Ortiz SL, Wanger AR, Norris SJ. 2001. Mycobacterial protein HbhA binds human complement component C3. Infect Immun 69:7501-7511. http://dx.doi.org/10.1128/IAI.69.12.7501-7511.2001.
41. Koch TK, Reuter M, Barthel D, Bohm S, van den Elsen J, Kraiczy P, Zipfel PF, Skerka C. 2012. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. PLoS One 7:e47638. http://dx.doi.org/10.1371/journal.pone.0047638.
42. Lee LY, Liang X, Hook M, Brown EL. 2004. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J Biol Chem 279:50710-50716. http://dx.doi.org/10.1074/jbc.M408570200.
43. Schlesinger LS, Horwitz MA. 1991. Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J Exp Med 174:1031-1038. http://dx .doi.org/10.1084/jem.174.5.1031.
44. Kunert A, Losse J, Gruszin C, Huhn M, Kaendler K, Mikkat S, Volke D, Hoffmann R, Jokiranta TS, Seeberger H, Moellmann U, Hellwage J, Zipfel PF. 2007. Immuneevasion of thehumanpathogenPseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol 179:2979-2988. http://dx.doi.org/10.4049/jimmunol.179.5.2979.
45. Feingold DS, Goldman JN, Kuritz HM. 1968. Locus of the action of serum and the role of lysozyme in the serum bactericidal reaction. J Bacteriol 96:2118-2126.
46. Feingold DS, Goldman JN, Kuritz HM. 1968. Locus of the lethal event in the serum bactericidal reaction. J Bacteriol 96:2127-2131.
47. Iida K, Whitlow MB, Nussenzweig V. 1989. Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components. J Exp Med 169:881-891. http://dx.doi.org/10.1084/jem.169.3.881.
48. Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. 1983. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 42:170-177.
49. Schiller NL. 1988. Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains. Infect Immun 56:632-639.
50. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. 2003. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 9:206-212. http://dx.doi.org/10.1038/nm814.
51. Krause A, Whu WZ, Qiu J, Wafadari D, Hackett NR, Sharma A, Crystal RG, Worgall S. 2013. RGD capsid modification enhances mucosal protective immunity of a nonhuman primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin Exp Immunol 173:230-241. http://dx .doi.org/10.1111/cei.12101.